In this episode of This Week in Virology, Dr. Daniel Griffin provides a clinical update covering a range of public health issues and infectious diseases. He begins by addressing the pervasive anti-science rhetoric and its real-world consequences, citing a violent attack at the CDC and its impact. Key updates include an outbreak of Vibrio vulnificus in coastal waters, the ongoing Legionnaires' disease cluster in Harlem, and a clinical trial demonstrating Ivermectin's efficacy in reducing malaria incidence.
Dr. Griffin highlights contrasting immunization guidelines, with the American Academy of Pediatrics releasing an evidence-based schedule that diverges from recent CDC recommendations, particularly regarding RSV, influenza, and COVID-19 for children. He reports on concerning increases in measles cases globally and discusses high pediatric flu mortality. For adults over 65, he emphasizes the superior effectiveness of high-dose influenza vaccines. The episode also touches on the association of Guillain-Barré Syndrome with certain RSV vaccines and rising COVID-19 wastewater levels. A significant new finding on accelerated vascular aging after COVID-19, especially in women, is discussed. The segment concludes with a call to support biomedical research and addresses listener questions on vaccine access, data transparency, and testing barriers, particularly for measles.
Clinical Update with Dr. Daniel Griffin
0:00 Consequences of Anti-Science Rhetoric: Dr. Griffin opens by discussing the real-world dangers of anti-science sentiment, including a violent attack on the CDC headquarters (August 8, 2025) which resulted in a police officer's death and injuries to buildings, driven by vaccine misinformation. This event is linked to broader issues like threats against scientists and a perceived undermining of public health institutions.
7:55 Vibrio Vulnificus Alert: The Massachusetts Department of Public Health warns about Vibrio vulnificus bacteria in coastal waters, linked to warm temperatures. Infections, often from open wounds or contaminated shellfish, can lead to severe, life-threatening illness, particularly in individuals with liver compromise.
10:17 Ivermectin for Malaria Control: A study in the New England Journal of Medicine shows that mass administration of Ivermectin reduced malaria infection incidence by 26% compared to Albendazole in coastal Kenya. The drug appears to act as both an antiparasitic and an insecticide, offering a "two-for-one" benefit, though concerns about resistance are raised.
14:31 Legionnaires' Disease Outbreak: An ongoing Legionnaires' disease outbreak in Harlem has seen 111 confirmed cases and 6 deaths as of August 21, 2025. Investigations have identified and are addressing contaminated cooling towers. Dr. Griffin provides a historical overview, distinguishing between Pontiac fever (Legionella infection without pneumonia) and Legionnaires' disease (with pneumonia).
20:26 AAP vs. CDC Immunization Schedule: The American Academy of Pediatrics (AAP) released its own evidence-based immunization schedule, which differs from recent CDC recommendations. The AAP explicitly addresses influenza, RSV, and COVID-19, advocating for broad vaccination, in contrast to what is characterized as a "compromised" CDC committee spreading misinformation.
22:07 RSV Vaccine Recommendations: AAP highlights RSV as a leading cause of infant hospitalizations. Recommendations include maternal vaccination or infant shots (Nirsevimab, Clurovimab) for babies in their first RSV season. For 8-19 month-olds at high risk, a second RSV season immunization is advised.
23:05 Influenza Vaccine Recommendations & Impact: AAP recommends annual flu shots for all children from six months, noting that 270 pediatric deaths occurred last flu season, mostly among healthy, unvaccinated children.
24:18 COVID-19 Vaccine Recommendations: AAP recommends COVID-19 vaccination for all children aged 16-23 months (due to similar risk as 65+ individuals), and a single annual dose for children 2-18 in high-risk groups or whose parents desire protection.
25:51 Global Measles Resurgence: Measles cases are rising significantly, with over 1,375 confirmed cases in the US (42 jurisdictions), 4,638 in Canada, and 526 in Israel (2 deaths). The Pan-American Health Organization reports over 10,000 cases and 18 deaths across 10 countries, a 34-fold increase from the previous year, with outbreaks concentrated in unvaccinated populations.
29:30 High-Dose Flu Vaccines for 65+: A study demonstrates that high-dose, adjuvanted, or recombinant influenza vaccines for adults aged 65 and older significantly reduce hospitalizations (63-67% lower risk) and all-cause mortality (74% lower risk) compared to standard-dose vaccines, regardless of frailty. Patients are encouraged to "shop around" for these preferred options.
32:35 RSV Vaccine and GBS Risk: The CDC recommends RSV vaccination for adults 75 and older, and for those 50-74 at increased risk of severe RSV. It's currently a one-time dose. A small risk of Guillain-Barré Syndrome (GBS) (7-9 excess cases per million vaccinated adults 60+) has been associated with GSK's Arexvy and Pfizer's Abrysvo, but not Moderna's mResvia.
34:31 COVID-19 Wastewater Trends & Vascular Aging: Wastewater surveillance indicates increasing COVID-19 activity nationally. A study published in the European Heart Journal (CARTESIAN study) reveals accelerated vascular aging (artery stiffening) after COVID-19 infection, particularly in women, even in non-hospitalized cases. This stiffening is associated with increased risks of hypertension, strokes, and heart attacks.
40:52 CDC Data Transparency Concerns: A listener email from a retired dentist criticizes the CDC's changing and limited reporting of measles data, suggesting potential political manipulation and contrasting it with more transparent data from Canada.
45:04 Paxlovid Access Barriers: A listener reports significant financial barriers to accessing Paxlovid, costing $279 with insurance and $1,200 without, highlighting challenges in obtaining effective COVID-19 treatments.
49:24 Alternative Measles Trackers: Listeners recommend Johns Hopkins and Brown University's Pandemic Center as alternative, more comprehensive sources for measles data, as they scrape information directly from state and county health departments.
51:33 Barriers to Measles Testing: A primary care doctor expresses concern over the Minnesota Department of Health's requirement to send measles tests directly to the department rather than local labs, viewing it as an unnecessary burden that will reduce testing rates.